Diffuse midline glioma (DMG) with H3K27M mutation is an aggressive and difficult to treat pediatric brain tumor. Recurrent gain of function mutations in H3.3 (H3.
* The research successfully identifies unique epigenetic patterns and tumor-originating proteins in the plasma, allowing for better differentiation of DMG patients from healthy individuals and those with other cancers.
* The method requires only a small blood sample and shows strong correlation with traditional imaging and DNA assessment techniques, highlighting its potential for non-invasive monitoring and diagnosis of DMG.